Physician profile
Pedro J Rivera
NPI 1174729396
$4,295.51
in general payments reported to CMS, 2019-2025
15 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $623 · 2021: $828 · 2022: $260 · 2023: $518 · 2024: $513 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.89 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,546.59 | 2019-2024 | Xarelto |
| Pfizer INC. | $565.64 | 2019-2024 | |
| Allergan, INC. | $443.93 | 2019-2020 | |
| Melinta Therapeutics, LLC | $425.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $396.32 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Csl Behring | $304.54 | 2023-2025 | Kcentra, Haegarda |
| E.R. Squibb & Sons, L.L.C. | $171.52 | 2019-2021 | |
| Chiesi USA, INC. | $164.28 | 2019-2025 | Kengreal |
| Abbvie INC. | $140.40 | 2024-2025 | |
| Vapotherm INC | $30.00 | 2021 | |
| Gilead Sciences, INC. | $24.62 | 2021 | |
| Mallinckrodt Hospital Products INC. | $22.28 | 2023 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $21.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.95 | 2023 | Jardiance |
| Nabriva Therapeutics, Plc | $18.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.